HC Wainwright Reaffirms Buy Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $15.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 396.69% from the stock’s previous close.

TCRX has been the topic of several other reports. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a research report on Tuesday, November 12th. Wedbush restated an “outperform” rating and issued a $7.00 price target (down from $10.00) on shares of TScan Therapeutics in a research report on Tuesday.

TScan Therapeutics Stock Performance

Shares of TScan Therapeutics stock opened at $3.02 on Wednesday. The stock’s fifty day moving average price is $4.87 and its 200-day moving average price is $5.91. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a 12 month low of $2.60 and a 12 month high of $9.69. The firm has a market cap of $161.18 million, a P/E ratio of -2.85 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. The business had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. On average, equities research analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Barbara Klencke purchased 5,000 shares of the company’s stock in a transaction on Monday, September 23rd. The shares were purchased at an average cost of $5.29 per share, with a total value of $26,450.00. Following the completion of the transaction, the director now owns 45,000 shares of the company’s stock, valued at $238,050. The trade was a 12.50 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.76% of the stock is owned by insiders.

Hedge Funds Weigh In On TScan Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP acquired a new stake in shares of TScan Therapeutics in the 2nd quarter valued at about $70,000. SG Americas Securities LLC purchased a new stake in TScan Therapeutics in the third quarter valued at approximately $78,000. The Manufacturers Life Insurance Company bought a new stake in shares of TScan Therapeutics during the 2nd quarter worth $90,000. XTX Topco Ltd purchased a new position in shares of TScan Therapeutics during the 3rd quarter valued at about $112,000. Finally, MetLife Investment Management LLC grew its stake in shares of TScan Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock valued at $116,000 after buying an additional 13,164 shares during the last quarter. Institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.